A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC

Drilon, Alexander E. ; Awad, Mark M. ; Gadgeel, Shirish M. ; Villaruz, Liza C ; Sabari, Joshua K. ; Perez, Javier ; Daly, Christopher ; Patel, Shraddha ; Li, Siyu ; Seebach, Frank A. ; Lowy, Israel ; Magnan, Heather D. ; Rietschel, Petra

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8593-TPS8593 [Periódico revisado por pares]

Texto completo disponível